Opinion
Video
The expert panel provides perspective on current therapeutic gaps and key barriers to care.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Kabiri discusses the large unmet need for decades of having a consistently formulated prescription product that addresses the evaporative dry eye disease (DED) component. This allows for aligned patient and provider perspectives on outcomes. A recently approved product helps address this need.
Haumschild asks about additional gaps a new DED product could address. Kabiri notes other forms of keratitis can arise from DED, interfere with treatment response, and lack a “bridge” product to rein these in. The new product targeting evaporative DED allows other metrics like corneal staining and tear breakup time to demonstrate improvement at predictable time points. This predictability can promote treatment compliance.
Haumschild asks about key patient challenges around DED diagnosis and access to appropriate treatments. Kabiri notes a growing younger patient demographic with more evaporative DED from digital device use. DED with an evaporative component can lead to secondary keratitis, glaucoma, drop tolerance, and related issues. Though immunomodulators help address inflammation, residual evaporative DED may persist. The recent FDA approval targeting evaporative DED and overall DED offers an exciting new option for this major unmet need.
Parekh also cites a newly approved treatment for a subset of blepharitis patients. Additional pipeline innovations offer promise for comprehensively addressing DED’s unmet needs in the future.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.